Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Worth a read for anyone following obesity care and real-world evidence: To view or add a comment, sign in A diagnostic paradox buried in the Lancet obesity framework: Patient A: HbA1c 6.1% + dyslipidemia meets definition of "clinical obesity" Patient B: HbA1c 6.8% (diagnosed T2DM) + normal lipids may not qualify as "clinical obesity" T2DM was excluded from the organ-dysfunction criteria despite: ~90% of T2DM patients being overweight or obese Strong mechanistic links to visceral & ectopic fat ~50% diabetes remission rate with intensive weight loss at 1 year This inconsistency may create real coverage and access problems
Pieber, M.L
obese ) Extreme overweight
This matters because much of the public buzz around these medicines is about weight loss, while many early launches may be positioned first through the diabetes route
US$ 20.75
US$ 27.12
US$ 26.78
US$ 22.78
US$ 24.11
